文献速递眼底病与葡萄膜炎

残余视网膜积液对雷珠单抗治疗新生血管性年龄相关性黄斑变性视功能的影响

Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2021-07-18

该研究基于HARBOR三期随机对照试验的事后分析,纳入917例接受雷珠单抗0.5或2.0 mg治疗的nAMD患者,评估残余视网膜下液(SRF)和/或视网膜内液(IRF)与最佳矫正视力(BCVA)的关系。结果显示,残余SRF者BCVA高于SRF消退者,而残余IRF者BCVA低于IRF消退者;残余SRF且无IRF者BCVA增益最大。

要点

  • 残余SRF与较好BCVA相关,残余IRF与较差BCVA相关。
  • 残余SRF且无IRF者BCVA增益最大,仅残余IRF者增益最小。
  • nAMD管理中需对残余视网膜积液进行细致评估和解读。

核心结论

  • 经基线BCVA校正后,至第24个月,残余SRF者视力结局优于SRF消退者,而残余IRF者视力结局劣于IRF消退者。
  • 残余视网膜积液的存在需要在nAMD管理背景下进行更复杂和细致的评估与解读。

研究设计与样本

  • 临床队列研究,基于HARBOR(NCT00891735)三期随机对照试验数据的事后分析。
  • 纳入917例≥50岁、基线/筛选/第1周存在视网膜下液和/或视网膜内液的亚中心凹nAMD患者。
  • 干预为玻璃体腔注射雷珠单抗0.5或2.0 mg(所有治疗组汇总)。

主要发现

  • 第12个月残余SRF者平均BCVA为58.8字母(95%CI 57.2-60.4),SRF消退者为53.5字母(95%CI 52.4-54.5);第24个月分别为59.3字母(95%CI 57.8-60.8)和53.5字母(95%CI 52.5-54.5)。
  • 至第12个月,残余SRF者较SRF消退者平均BCVA变化多+2.4字母(95%CI +0.1至+4.7),而残余IRF者较IRF消退者少-3.5字母(95%CI -5.8至-1.2)。
  • 残余SRF且无IRF者平均BCVA增益最大(第12个月+14.1字母;第24个月+13.2字母),其次为SRF/IRF均消退者(第12个月+10.6字母;第24个月+10.0字母)、残余SRF/IRF者(第12个月+7.2字母;第24个月+8.5字母)、仅残余IRF者(第12个月+5.5字母;第24个月+3.6字母)。

临床怎么用

  • 在nAMD抗VEGF治疗随访中,应区分残余SRF与残余IRF对视力预后的不同影响。
  • 残余IRF可能提示视力预后较差,需更细致评估和个体化管理。

局限性

  • 本研究为临床试验数据的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the relationship between retinal fluid and vision in ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD). DESIGN: Clinical cohort study using post hoc analysis of clinical trial data. METHODS: We assessed data from HARBOR (NCT00891735), a phase III, randomized, controlled trial. We reviewed 917 patients ≥50 years of age with subfoveal nAMD associated with subretinal (SRF) and/or intraretinal fluid (IRF) at baseline, screening, or week 1. The intervention was intravitreal ranibizumab 0.5 or 2.0 mg (all treatment arms pooled). Outcomes included mean best-corrected visual acuity (BCVA) and BCVA change from baseline at months (M) 12 and 24 evaluated by the presence/absence of SRF and/or IRF. RESULTS: Baseline BCVA was higher with residual vs resolved SRF at M12 (mean [95% confidence interval {CI}] 58.8 letters [57.2-60.4] vs 53.5 [52.4-54.5]) and M24 (59.3 letters [57.8-60.8] vs 53.5 [52.5-54.5]). Mean BCVA change (adjusted for baseline) to M12 was greater with residual vs resolved SRF (mean difference [95% CI], +2.4 letters [+0.1 to +4.7]), but lower with residual vs resolved IRF (-3.5 letters [-5.8 to -1.2]). Eyes with residual SRF (no IRF) exhibited the largest mean BCVA gains (M12, +14.1 letters; M24, +13.2 letters), followed by resolved SRF/IRF (M12, +10.6 letters; M24, +10.0 letters), residual SRF/IRF (M12, +7.2 letters; M24, +8.5 letters), and residual IRF only (M12, +5.5 letters; M24, +3.6 letters). CONCLUSIONS: Vision outcomes (adjusted for baseline BCVA) through M24 were better in ranibizumab-treated eyes with residual vs resolved SRF, and worse with residual vs resolved IRF. Presence of residual retinal fluid requires a more complex and nuanced assessment and interpretation in the context of nAMD management.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Holekamp NM, Sadda S, Sarraf D, et al. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2021. PMID: 34289338. doi:10.1016/j.ajo.2021.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。